Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Operating Leases (2019 - 2025)

Ocular Therapeutix (OCUL) has 7 years of Operating Leases data on record, last reported at $2.8 million in Q4 2025.

  • For Q4 2025, Operating Leases fell 47.33% year-over-year to $2.8 million; the TTM value through Dec 2025 reached $2.8 million, down 47.33%, while the annual FY2025 figure was $2.8 million, 47.33% down from the prior year.
  • Operating Leases reached $2.8 million in Q4 2025 per OCUL's latest filing, down from $3.6 million in the prior quarter.
  • Across five years, Operating Leases topped out at $8.7 million in Q4 2022 and bottomed at $2.8 million in Q4 2025.
  • Average Operating Leases over 5 years is $6.0 million, with a median of $6.0 million recorded in 2021.
  • Peak YoY movement for Operating Leases: surged 57.29% in 2023, then plummeted 47.33% in 2025.
  • A 5-year view of Operating Leases shows it stood at $5.9 million in 2021, then skyrocketed by 46.49% to $8.7 million in 2022, then dropped by 20.74% to $6.9 million in 2023, then fell by 22.29% to $5.3 million in 2024, then tumbled by 47.33% to $2.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $2.8 million in Q4 2025, $3.6 million in Q3 2025, and $4.4 million in Q2 2025.